87 related articles for article (PubMed ID: 10968135)
1. Pilot study of formestane in postmenopausal women with breast cancer.
Joseph JK; Lim AK
Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
[TBL] [Abstract][Full Text] [Related]
2. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
[TBL] [Abstract][Full Text] [Related]
3. Severe immune thrombocytopenia during formestane treatment.
Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
[TBL] [Abstract][Full Text] [Related]
4. Formestane for advanced breast cancer in postmenopausal women.
Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
[No Abstract] [Full Text] [Related]
5. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
6. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
7. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
8. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
10. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
11. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
12. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
13. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
Dowsett M
Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
16. Proper sequence of endocrine therapies in advanced breast cancer.
Rose C
Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
[TBL] [Abstract][Full Text] [Related]
17. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
[TBL] [Abstract][Full Text] [Related]
19. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
20. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
